Literature DB >> 18443355

The role of osteopontin in the development of albuminuria.

Johan Lorenzen1, Rajshree Shah, Alisha Biser, Serban A Staicu, Thiruvur Niranjan, Ana Maria Garcia, Antje Gruenwald, David B Thomas, Ibrahim F Shatat, Katarine Supe, Robert P Woroniecki, Katalin Susztak.   

Abstract

Several gene array studies have suggested that osteopontin (Opn) expression strongly correlates with albuminuria and glomerular disease. Urinary Opn concentration and kidney Opn immunoreactivity were found to be increased in patients with steroid-sensitive nephrotic syndrome. In addition, renal Opn mRNA was increased in the Ins2(Akita) mouse model of type 1 diabetic nephropathy, in the LPS-induced albuminuria model, and in glomeruli of puromycin aminonucleotide-induced nephrotic rats. Opn knockout mice did not develop albuminuria in response to LPS injection, and Opn knockout mice were protected from diabetes-induced albuminuria and mesangial expansion. In the glomerulus, Opn immunostaining was increased specifically in podocytes. Treatment of podocytes with recombinant Opn activated the NF-kappaB pathway, increased expression of urokinase plasminogen activator and matrix metalloproteinases 2 and 9, and increased podocyte motility. Taken together, these results indicate that Opn plays an important role in the development of albuminuria, possibly by modulating podocyte signaling and motility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443355      PMCID: PMC2386721          DOI: 10.1681/ASN.2007040486

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

1.  Regulation of collagenase-3 and osteocalcin gene expression by collagen and osteopontin in differentiating MC3T3-E1 cells.

Authors:  Richard C D'Alonzo; Aaron J Kowalski; David T Denhardt; G Allen Nickols; Nicola C Partridge
Journal:  J Biol Chem       Date:  2002-04-18       Impact factor: 5.157

2.  Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling.

Authors:  Katsuhiko Asanuma; Etsuko Yanagida-Asanuma; Christian Faul; Yasuhiko Tomino; Kwanghee Kim; Peter Mundel
Journal:  Nat Cell Biol       Date:  2006-04-16       Impact factor: 28.824

3.  Osteopontin expression in human crescentic glomerulonephritis.

Authors:  K L Hudkins; C M Giachelli; F Eitner; W G Couser; R J Johnson; C E Alpers
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

4.  Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.

Authors:  Csaba Szabó; Alisha Biser; Rita Benko; Erwin Böttinger; Katalin Suszták
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

5.  Lack of in vivo function of osteopontin in experimental anti-GBM nephritis.

Authors:  John Michael Bonvini; Ursula Schatzmann; Beatrice Beck-Schimmer; Li Kang Sun; Susan R Rittling; David T Denhardt; Michel LE Hir; Rudolf P Wüthrich
Journal:  J Am Soc Nephrol       Date:  2000-09       Impact factor: 10.121

6.  Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell.

Authors:  K De Bosscher; W Vanden Berghe; L Vermeulen; S Plaisance; E Boone; G Haegeman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

7.  Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress.

Authors:  Nicole Endlich; Masataka Sunohara; Wilfried Nietfeld; Eryk W Wolski; Daniel Schiwek; Bettina Kränzlin; Norbert Gretz; Wilhelm Kriz; Holger Eickhoff; Karlhans Endlich
Journal:  FASEB J       Date:  2002-09-19       Impact factor: 5.191

8.  Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents.

Authors:  Steve I Shen; Phanidhara R Kotamraj; Shiladitya Bhattacharya; Xiaoling Li; Bhaskara R Jasti
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

9.  Modification of kidney barrier function by the urokinase receptor.

Authors:  Changli Wei; Clemens C Möller; Mehmet M Altintas; Jing Li; Karin Schwarz; Serena Zacchigna; Liang Xie; Anna Henger; Holger Schmid; Maria P Rastaldi; Peter Cowan; Matthias Kretzler; Roberto Parrilla; Moïse Bendayan; Vineet Gupta; Boris Nikolic; Raghu Kalluri; Peter Carmeliet; Peter Mundel; Jochen Reiser
Journal:  Nat Med       Date:  2007-12-16       Impact factor: 53.440

10.  Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.

Authors:  Michael Zeisberg; Mona Khurana; Velidi H Rao; Dominic Cosgrove; Jean-Philippe Rougier; Michelle C Werner; Charles F Shield; Zena Werb; Raghu Kalluri
Journal:  PLoS Med       Date:  2006-03-07       Impact factor: 11.069

View more
  41 in total

Review 1.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

2.  Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.

Authors:  Li Zuo; Yong Du; Man Lu; Junling Gao; Ruolei Hu; Sumei Zhang; Yi Wang; Huaqing Zhu; Qing Zhou; Wei Wei; Yuan Wang
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

3.  Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival.

Authors:  Hideki Kato; Antje Gruenwald; Jung Hee Suh; Jeffrey H Miner; Laura Barisoni-Thomas; Makoto M Taketo; Christian Faul; Sarah E Millar; Lawrence B Holzman; Katalin Susztak
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

Review 4.  Cell biology and pathology of podocytes.

Authors:  Anna Greka; Peter Mundel
Journal:  Annu Rev Physiol       Date:  2011-11-04       Impact factor: 19.318

5.  Performance of novel kidney biomarkers in preclinical toxicity studies.

Authors:  Dana Hoffmann; Melanie Adler; Vishal S Vaidya; Eva Rached; Laoighse Mulrane; William M Gallagher; John J Callanan; Jean C Gautier; Katja Matheis; Frank Staedtler; Frank Dieterle; Arnd Brandenburg; Alexandra Sposny; Philip Hewitt; Heidrun Ellinger-Ziegelbauer; Joseph V Bonventre; Wolfgang Dekant; Angela Mally
Journal:  Toxicol Sci       Date:  2010-01-29       Impact factor: 4.849

6.  Inhibition of the TRPC5 ion channel protects the kidney filter.

Authors:  Thomas Schaldecker; Sookyung Kim; Constantine Tarabanis; Dequan Tian; Samy Hakroush; Philip Castonguay; Wooin Ahn; Hanna Wallentin; Hans Heid; Corey R Hopkins; Craig W Lindsley; Antonio Riccio; Lisa Buvall; Astrid Weins; Anna Greka
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

7.  Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.

Authors:  Daniel T Meehan; Duane Delimont; Linda Cheung; Marisa Zallocchi; Steven C Sansom; J David Holzclaw; Velidi Rao; Dominic Cosgrove
Journal:  Kidney Int       Date:  2009-08-26       Impact factor: 10.612

Review 8.  Proteinuria: an enzymatic disease of the podocyte?

Authors:  Peter Mundel; Jochen Reiser
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

9.  The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Authors:  A M D Watson; J Li; C Schumacher; M de Gasparo; B Feng; M C Thomas; T J Allen; M E Cooper; K A M Jandeleit-Dahm
Journal:  Diabetologia       Date:  2009-10-28       Impact factor: 10.122

10.  The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability.

Authors:  Eun Young Lee; Choon Hee Chung; Charbel C Khoury; Tet Kin Yeo; Petr E Pyagay; Amy Wang; Sheldon Chen
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.